title: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.
abstract: BACKGROUND
  Pilot studies of interferon alpha (IFN-alpha) suggest a high remission rate in the treatment of active ulcerative colitis. We evaluated the safety of pegylated interferon alpha (PegIFN) and its role in induction of remission in patients with active ulcerative colitis, in a multicentre placebo controlled trial.
  
  
  METHODS
  Sixty patients with a clinical activity score (CAI) of >6 were randomised to receive placebo (n=20), PegIFN 0.5 microg/kg (n=19), or PegIFN 1.0 microg/kg body weight (n=21) once weekly (PegIntron; Schering-Plough, USA) over 12 weeks. Patients receiving 5-aminosalicylates, steroids, and/or azathioprine in stable dosages were included.
  
  
  RESULTS
  Serious adverse events were seen in none of the placebo patients, in 3/19 patients in the PegIFN 0.5 microg/kg group (hospitalisation due to disease flare up n=3), and in 3/21 in the PegIFN 1.0 microg/kg group (hospitalisation due to disease flare up n=1; thrombosis n=1; grand mal seizure n=1). Otherwise, we observed only minor IFN-alpha side effects. Clinical remission rates at week 12 (CAI < or =4) were 7/20 (35%) in the placebo, 9/19 (47%) in the PegIFN 0.5 microg/kg group, and 7/21 (33%) in the PegIFN 1.0 microg/kg group (NS). Early withdrawal from the study was observed in 11/20 placebo patients, in 6/19 in the PegIFN 0.5 microg/kg group, and in 10/21 in the PegIFN 1.0 microg/kg group, mainly due to lack of efficacy. The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85).
  
  
  CONCLUSIONS
  PegIFN is safe but not effective, at the dosages used, in patients with ulcerative colitis.
authors.affiliation: Department of Gastroenterology and Hepatology and Biostatistics, University Hospital Innsbruck, Austria. Herbert.Tilg@uibk.ac.at
authors.forename: H
authors.initials: H
authors.lastname: Tilg
authors.forename: H
authors.initials: H
authors.lastname: Vogelsang
authors.forename: O
authors.initials: O
authors.lastname: Ludwiczek
authors.forename: H
authors.initials: H
authors.lastname: Lochs
authors.forename: A
authors.initials: A
authors.lastname: Kaser
authors.forename: J-F
authors.initials: JF
authors.lastname: Colombel
authors.forename: H
authors.initials: H
authors.lastname: Ulmer
authors.forename: P
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: S
authors.initials: S
authors.lastname: Krüger
authors.forename: A
authors.initials: A
authors.lastname: Cortot
authors.forename: G
authors.initials: G
authors.lastname: D'Haens
authors.forename: M
authors.initials: M
authors.lastname: Harrer
authors.forename: C
authors.initials: C
authors.lastname: Gasche
authors.forename: F
authors.initials: F
authors.lastname: Wrba
authors.forename: I
authors.initials: I
authors.lastname: Kuhn
authors.forename: W
authors.initials: W
authors.lastname: Reinisch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy*; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009961:Orosomucoid / Q000032:analysis; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D005765:Gastrointestinal Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009961:Orosomucoid; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D002097:C-Reactive Protein; C100416:peginterferon alfa-2a